79 related articles for article (PubMed ID: 17009339)
1. Pharmacokinetic interaction between fluvastatin and diltiazem in rats.
Choi JS; Piao YJ; Han HK
Biopharm Drug Dispos; 2006 Dec; 27(9):437-41. PubMed ID: 17009339
[TBL] [Abstract][Full Text] [Related]
2. Enhanced oral exposure of diltiazem by the concomitant use of naringin in rats.
Choi JS; Han HK
Int J Pharm; 2005 Nov; 305(1-2):122-8. PubMed ID: 16226412
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats.
Qiang F; Lee BJ; Lee W; Han HK
Eur J Pharm Sci; 2009 Jun; 37(3-4):413-7. PubMed ID: 19428223
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interaction between diltiazem and morin, a flavonoid, in rats.
Choi JS; Han HK
Pharmacol Res; 2005 Nov; 52(5):386-91. PubMed ID: 16002304
[TBL] [Abstract][Full Text] [Related]
5. Effect of hesperidin on the oral pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats.
Cho YA; Choi DH; Choi JS
J Pharm Pharmacol; 2009 Jun; 61(6):825-9. PubMed ID: 19505375
[TBL] [Abstract][Full Text] [Related]
6. Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats.
Hong SP; Choi DH; Choi JS
Cardiovasc Ther; 2008; 26(4):269-75. PubMed ID: 19035878
[TBL] [Abstract][Full Text] [Related]
7. Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin.
Choi DH; Choi JS; Li C; Choi JS
Pharmacol Rep; 2011; 63(6):1574-82. PubMed ID: 22358108
[TBL] [Abstract][Full Text] [Related]
8. Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats.
Li C; Lee MY; Choi JS
Pharmazie; 2010 Jul; 65(7):510-4. PubMed ID: 20662320
[TBL] [Abstract][Full Text] [Related]
9. Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin.
Hong SP; Yang JS; Han JY; Ha SI; Chung JW; Koh YY; Chang KS; Choi DH
J Pharm Pharmacol; 2011 Jan; 63(1):129-35. PubMed ID: 21189658
[TBL] [Abstract][Full Text] [Related]
10. Effect of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in rats.
Choi DH; Chang KS; Hong SP; Choi JS; Han HK
Biopharm Drug Dispos; 2008 Jan; 29(1):45-50. PubMed ID: 17941000
[TBL] [Abstract][Full Text] [Related]
11. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats.
Choi BC; Choi JS; Han HK
Int J Pharm; 2006 Oct; 323(1-2):81-5. PubMed ID: 16806758
[TBL] [Abstract][Full Text] [Related]
12. Effect of atorvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats.
Hong SP; Chang KS; Choi DH; Choi JS
Arch Pharm Res; 2007 Jan; 30(1):90-5. PubMed ID: 17328247
[TBL] [Abstract][Full Text] [Related]
13. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin.
Transon C; Leemann T; Vogt N; Dayer P
Clin Pharmacol Ther; 1995 Oct; 58(4):412-7. PubMed ID: 7586933
[TBL] [Abstract][Full Text] [Related]
14. Effects of epigallocatechin gallate on the bioavailability and pharmacokinetics of diltiazem in rats.
Li C; Choi JS
Pharmazie; 2008 Nov; 63(11):815-8. PubMed ID: 19069242
[TBL] [Abstract][Full Text] [Related]
15. Development and pharmacology of fluvastatin.
Jokubaitis LA
Br J Clin Pract Suppl; 1994 Dec; (77):11-5. PubMed ID: 19489169
[TBL] [Abstract][Full Text] [Related]
16. Development and pharmacology of fluvastatin.
Jokubaitis LA
Br J Clin Pract Suppl; 1996 Jan; 77A():11-5. PubMed ID: 8729584
[TBL] [Abstract][Full Text] [Related]
17. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
Fischer V; Johanson L; Heitz F; Tullman R; Graham E; Baldeck JP; Robinson WT
Drug Metab Dispos; 1999 Mar; 27(3):410-6. PubMed ID: 10064574
[TBL] [Abstract][Full Text] [Related]
18. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin.
Hong SP; Chang KS; Koh YY; Choi DH; Choi JS
Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809
[TBL] [Abstract][Full Text] [Related]
19. Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers.
Boralli VB; Coelho EB; Sampaio SA; Marques MP; Lanchote VL
J Clin Pharmacol; 2009 Feb; 49(2):205-11. PubMed ID: 19033449
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat.
Zhou R; Xu Q; Zheng P; Yan L; Zheng J; Dai G
Eur J Pharmacol; 2008 May; 586(1-3):244-50. PubMed ID: 18384769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
